Skip to main
CAPR

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics Inc. exhibits a strong positive outlook due to the remarkable valuation increase of its deramiocel therapy for DMD cardiomyopathy, rising to $2.30 billion from $794 million, reflecting the therapy's promising clinical trial results. The recent Phase III HOPE-3 data highlights significant improvements in key clinical metrics, including a 1.0 point enhancement in PUL 2.0 and positive trends in Late Gadolinium Enhancement, supporting the efficacy of deramiocel. Furthermore, the strategic partnership with NSPharma is expected to drive substantial net sales and enhance the company’s revenue potential, bolstering its growth prospects in the clinical-stage biotechnology sector.

Bears say

Capricor Therapeutics faces substantial challenges, including the slower-than-expected ramp of its product pipeline, which may lead to the need for additional equity or debt financing on unfavorable terms, thus potentially diluting shareholder value. The company's primary product, deramiocel, carries significant clinical risks related to safety, efficacy, and regulatory approval, raising concerns about its market success and overall revenue generation. Additionally, recent data indicating a steady decline in left ventricular ejection fraction (LVEF) in DMD patients suggests that time is of the essence, as delays in product launch or market penetration may limit the therapeutic's impact and financial performance.

Capricor Therapeutics (CAPR) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Capricor Therapeutics (CAPR) has a Strong Buy consensus rating as of Jan 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.